title: Novel RNA interference-based therapies for sepsis.
abstract: BACKGROUND
  Sepsis is an extremely fast-paced disease, initiated by an infection that can progress to multiple organ dysfunction and death. The complexity associated with sepsis makes the therapies difficult to develop. Moreover, the 'one-fits-all' kind of therapy is far from being realistic.
  
  
  METHODS
  This review provides a conspectus of the current results of sepsis therapies and their benefits, focusing on the development of small interfering RNA (siRNA) therapeutics for targeting immune cells and sepsis pathways.
  
  
  CONCLUSIONS
  The question, 'When will an effective therapy for sepsis be available for patients?' remains unanswered. New RNA interference-mediated therapies are emerging as novel approaches for the treatment of sepsis by downregulating key inflammatory cytokine expression. Strategies that exploit multimodal gene silencing using siRNA and targeted delivery systems are discussed in this review. Some of these strategies have shown positive results in preclinical model of sepsis.
authors.affiliation: Northeastern University, School of Pharmacy, Department of Pharmaceutical Sciences , 140 The Fenway Building, R170, 360 Huntington Avenue, Boston, MA 02115 , USA.
authors.forename: Verbena Y
authors.initials: VY
authors.lastname: Kosovrasti
authors.forename: Dmitriy
authors.initials: D
authors.lastname: Lukashev
authors.forename: Lubomir V
authors.initials: LV
authors.lastname: Nechev
authors.forename: Mansoor M
authors.initials: MM
authors.lastname: Amiji
mesh_terms: D000818:Animals; D016207:Cytokines / Q000235:genetics / Q000502:physiology; D016503:Drug Delivery Systems; D020868:Gene Silencing; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000473:pathology; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D016207:Cytokines; D034741:RNA, Small Interfering